Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Fujian Haixi Pharmaceuticals CoHKSE:02637 +3.28%23 Piotroski F-Score is 7 as of Aug. 16, 2026, which is at its 10-year median of 7.00. GuruFocus rates HKSE:02637 with a GF Score™ of 23/100. The stock has 2 warning signs investors should review. Among 978 Drug Manufacturers companies, Fujian Haixi Pharmaceuticals Co ranks better than 91.92% on this metric.
Good Sign:
Piotroski F-Score is 7, indicates a very healthy situation.
The zones of discrimination were as such:
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Fujian Haixi Pharmaceuticals Co has an F-score of 7. It is a good or high score, which usually indicates a very healthy situation.
The historical rank and industry rank for Fujian Haixi Pharmaceuticals Co's Piotroski F-Score or its related term are showing as below:
HKSE:02637'
s Piotroski F-Score Range Over the Past 10 Years
Min: 6 Med: 7 Max: 7
Current: 7
During the past 4 years, the highest Piotroski F-Score of Fujian Haixi Pharmaceuticals Co was 7. The lowest was 6. And the median was 7.
Fujian Haixi Pharmaceuticals Co (HKSE:02637) Piotroski F-Score Explanation
The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.
He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.
He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.
What he found was something that exceeded his most optimistic expectations.
Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.
Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).
Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.
Fujian Haixi Pharmaceuticals Co Piotroski F-Score Related Terms
Fujian Haixi Pharmaceuticals Co Piotroski F-Score Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fujian Haixi Pharmaceuticals Co Piotroski F-Score Chart
Fujian Haixi Pharmaceuticals Co Annual Data
Trend
Dec22
Dec23
Dec24
Dec25
Piotroski F-Score
N/A
N/A
6.00
7.00
Fujian Haixi Pharmaceuticals Co Semi-Annual Data
Dec22
Dec23
Dec24
Dec25
Piotroski F-Score
N/A
N/A
6.00
7.00
HKSE:02637 vs ZTS: Piotroski F-Score Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Fujian Haixi Pharmaceuticals Co's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fujian Haixi Pharmaceuticals Co Piotroski F-Score vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Fujian Haixi Pharmaceuticals Co's Piotroski F-Score distribution charts can be found below:
* The bar in red indicates where Fujian Haixi Pharmaceuticals Co's Piotroski F-Score falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.
Profitability
Question 1. Return on Assets (ROA)
Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
Fujian Haixi Pharmaceuticals Co's current Net Income (TTM) was 195.6.
==> Positive ==> Score 1.
Question 2. Cash Flow Return on Assets (CFROA)
Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
Fujian Haixi Pharmaceuticals Co's current Cash Flow from Operations (TTM) was 176.6.
==> Positive ==> Score 1.
Question 3. Change in Return on Assets
Compare this year's return on assets (1) to last year's return on assets.
Fujian Haixi Pharmaceuticals Co's return on assets of this year was 0.24234944. Fujian Haixi Pharmaceuticals Co's return on assets of last year was 0.23654643.
==> This year is higher. ==> Score 1.
Question 4. Quality of Earnings (Accrual)
Compare Cash flow return on assets (2) to return on assets (1)
Fujian Haixi Pharmaceuticals Co's gearing of this year was 0.019047. Fujian Haixi Pharmaceuticals Co's gearing of last year was 0.04845297.
==> This year is lower or equal to last year. ==> Score 1.
Question 6. Change in Working Capital (Liquidity)
Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.
Score 1 if this year's current ratio is higher, 0 if it's lower
Fujian Haixi Pharmaceuticals Co's current ratio of this year was 6.31014041. Fujian Haixi Pharmaceuticals Co's current ratio of last year was 1.90175623.
==> This year's current ratio is higher. ==> Score 1.
Question 7. Change in Shares in Issue
Compare the number of shares in issue this year, to the number in issue last year.
Score 0 if there is larger number of shares in issue this year, 1 otherwise.
Fujian Haixi Pharmaceuticals Co's number of shares in issue this year was 69.507. Fujian Haixi Pharmaceuticals Co's number of shares in issue last year was 78.707.
==> There is smaller number of shares in issue this year, or the same. ==> Score 1.
Efficiency
Question 8. Change in Gross Margin
Compare this year's gross margin (Gross Profit divided by sales) to last year's.
Score 1 if this year's gross margin is higher, 0 if it's lower.
Fujian Haixi Pharmaceuticals Co's gross margin of this year was 0.83377685. Fujian Haixi Pharmaceuticals Co's gross margin of last year was 0.82967262.
==> This year's gross margin is higher. ==> Score 1.
Question 9. Change in asset turnover
Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.
Score 1 if this year's asset turnover ratio is higher, 0 if it's lower
Fujian Haixi Pharmaceuticals Co's asset turnover of this year was 0.79723954. Fujian Haixi Pharmaceuticals Co's asset turnover of last year was 0.81123403.
==> Last year's asset turnover is higher ==> Score 0.
Evaluation
Piotroski F-Score
=
Que. 1
+
Que. 2
+
Que. 3
+
Que. 4
+
Que. 5
+
Que. 6
+
Que. 7
+
Que. 8
+
Que. 9
=
1
+
1
+
1
+
0
+
1
+
1
+
1
+
1
+
0
=
7
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Fujian Haixi Pharmaceuticals Co has an F-score of 7. It is a good or high score, which usually indicates a very healthy situation.
Fujian Haixi Pharmaceuticals Co (HKSE:02637) has a Piotroski F-Score of 7 as of Aug. 16, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Fujian Haixi Pharmaceuticals Co and its competitors. This is near median its historical median of 7.00. Over the past decade, Fujian Haixi Pharmaceuticals Co's Piotroski F-Score has ranged from 6.00 to 7.00. According to the industry distribution chart, Fujian Haixi Pharmaceuticals Co ranks #79 out of 978 companies in the Drug Manufacturers industry, placing it in the top 8.1%.
Is Fujian Haixi Pharmaceuticals Co's Piotroski F-Score too high?
Fujian Haixi Pharmaceuticals Co's current Piotroski F-Score of 7 is near median its 10-year median of 7.00. Over the past 10 years, this metric has ranged from a low of 6.00 to a high of 7.00. The Drug Manufacturers industry median Piotroski F-Score is 5.00. Fujian Haixi Pharmaceuticals Co's value of 7 is 40% above this industry median. Based on the distribution chart, Fujian Haixi Pharmaceuticals Co ranks #79 out of 978 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Fujian Haixi Pharmaceuticals Co has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Fujian Haixi Pharmaceuticals Co's Piotroski F-Score compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Fujian Haixi Pharmaceuticals Co ranks #79 out of 978 companies for Piotroski F-Score. This places Fujian Haixi Pharmaceuticals Co in the top 8% of its industry — outperforming the majority of peers. The industry median Piotroski F-Score is 5.00. Fujian Haixi Pharmaceuticals Co's value of 7 is 40% above this benchmark. Historically, Fujian Haixi Pharmaceuticals Co's own Piotroski F-Score has ranged from 6.00 to 7.00 over the past decade. While the company's 10-year median is 7.00 vs. the industry median of 5.00, Fujian Haixi Pharmaceuticals Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Drug Manufacturers company?
The median Piotroski F-Score among Drug Manufacturers companies is 5.00, based on 978 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Fujian Haixi Pharmaceuticals Co's current Piotroski F-Score of 7 is 40% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Fujian Haixi Pharmaceuticals Co and its competitors. For the Drug Manufacturers industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Fujian Haixi Pharmaceuticals Co's current Piotroski F-Score is 7, which is near median its own 10-year median of 7.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fujian Haixi Pharmaceuticals Co stock overvalued right now?
Fujian Haixi Pharmaceuticals Co (HKSE:02637) has a current Piotroski F-Score of 7. The current Piotroski F-Score is 7, which is near median its 10-year median of 7.00 and 40% above the Drug Manufacturers industry median of 5.00. Fujian Haixi Pharmaceuticals Co's overall GF Score™ is 23/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Fujian Haixi Pharmaceuticals Co (HKSE:02637), the current Piotroski F-Score is 7 as of Aug. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Fujian Haixi Pharmaceuticals Co Ltd is a commercial-stage pharmaceutical company that integrates R&D, production and sales capacities, with a pipeline of inventive drug candidates. It has a diversified product portfolio and pipeline in the fastest growing therapeutic areas in China. The company's commercialized product portfolio consisted of generic drugs for digestive system diseases, cardiovascular system diseases, endocrine system diseases, nervous system diseases and inflammatory diseases. Its inventive drug pipeline focuses on drug candidates in a variety of indications, including one potential first-in-class oncology drug candidate, one potential first oral drug therapy for wet age-related macular degeneration /diabetic macular edema /retinal vein occlusion.
23GF Score
Get the complete analysis for HKSE:02637
Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02637 has been successfully added to your 
